ADAM10 AS A CANDIDATE BIOMARKER FOR ALZHEIMER\'S DISEASE

2014 Alzheimer's Association International Conference Session date: July 14, 2014 Session number: P2 Session title: Poster Monday Presentation number: P2-070 ADAM10 as a candidate biomarker for Alzheimer's disease Jessyka Maria de França Bram1, Patricia Regina Manzine2, Elizabeth Joan Barham2, Francisco A.C. Vale3, Heloisa S. Selistre-de-Araújo3, Sofia Cristina Iost Pavarini4, Marcia Regina Cominetti2, 1Laboratory of Neuroscience - LIM-27 - Institute of Psychiatry - University of Sao Paulo, São Paulo, Brazil; 2Federal University of São Carlos, São Carlos, Sao Paulo, Brazil; 3 Federal University of Sao Carlos, Sao Carlos, Sao Paulo, Brazil; 4Federal University of São Carlos, São Carlos, Sao Paulo, Brazil, Sao Paulo, Brazil. Background: *********** Methods: It was a case-control, cross-sectional and descriptive study, approved by The Ethics Committee on Human Research of the Federal University of São Carlos, No. 427/2009, which was conducted with 19 subjects distributed into two distinct groups, one by AD patients and another by healthy elderly. Extensive exclusion criteria were applied, and the application of instruments such as the Clinical Dementia Rating (CDR) and MMSE was used. In the second stage of the study, blood samples were collected from subjects measure the platelet ADAM10 expression levels. Several parameters were analyzed in both groups, among them gender, age and scholarity. Results: The results revealed a decreased expression of ADAM10 in patients with AD compared to the control group (p